콘텐츠로 건너뛰기
Merck
  • Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation.

Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation.

Journal of molecular histology (2014-07-17)
Ting Zhu, Zhengxiang Ji, Caixia Xu, Zhiyang Peng, Liang Gu, Rui Zhang, Yangchen Liu
초록

Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) was reported to be implicated in various cellular processes and involved in control of cell cycle regulation and transcription. It may play a critical role in oncogenesis. In this study, to investigate the potential roles of SGTA in breast cancer, expression patterns, interaction and the correlation with clinical/prognostic factors of SGTA and Ki-67 were examined among patients with breast cancer. Immunohistochemistry and Western blot analysis were performed for SGTA in 100 breast carcinoma samples. The data were correlated with clinicopathological features. The univariate and multivariate survival analyses were also performed to determine the prognostic significance. We found that SGTA was overexpressed in breast carcinoma compared with the adjacent normal tissues. High expression of SGTA was positively associated with histological grade (P = 0.002) and Ki-67 (P = 0.001). Univariate analysis showed that SGTA expression was associated with a poor prognosis (P = 0.002). Kaplan-Meier survival curves of the study population showed that high expression level of SGTA significantly correlated with short-term survival. While in vitro, SGTA depletion by small interfering RNA inhibited cell proliferation and cell cycle in breast cancer cell lines. Western blot analyses showed that SGTA depletion decreased cyclin A, cyclin B and CDK2, whereas increased p27 levels. Additionally, treatment of phosphatidylinositol 3-kinase inhibitor LY294002 could arrest cells growth and diminish SGTA expression. These results suggested that SGTA overexpression was involved in the pathogenesis of breast cancer which might serve as a future target for novel treatment in breast cancer.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Propidium iodide, ≥94% (HPLC)
Sigma-Aldrich
Propidium iodide solution
Sigma-Aldrich
Monoclonal Anti-SGTA antibody produced in mouse, clone 2E11, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human SGTA
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Sgta